Nanobiotix offers upside via broad radiotherapy platform adoption but faces clinical, operational, and dilution risks. Read ...
Is CCI a good stock to buy? We came across a bullish thesis on Crown Castle Inc. on The Mispricing Desk’s Substack. In this ...
Health on MSN
How is indolent systemic mastocytosis (ISM) treated?
Medically reviewed by Gagandeep Brar, MD Avoid triggers, but carry an epinephrine pen for emergency treatment of anaphylaxis ...
The Danaher company expands its collaboration with AstraZeneca and Daiichi Sankyo to develop an end-to-end system for TROP2 ...
Researchers discovered that mutations linked to blood cancers may help trigger Alzheimer’s disease by creating overly ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association ...
An experimental treatment that resets a malfunctioning immune system has put the disease lupus into remission in early UK ...
A Cambridge biotech company is laying off 85% of staff and ending its sickle cell drug after the FDA cited unacceptable ...
(Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, ...
At the RP2D and maximum tolerated dose (100 µg,) cemsidomide achieved a 53% overall response rate (ORR). At the 75 µg dose level, cemsidomide achieved a 40% ORR. Across all doses evaluated, ...
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ...
Prenzler sees upside in stem cell sector with investment case being driven by several positive tailwinds and names three ASX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results